PharmAlliance project evolves into new international data science network to optimise dementia medication use
The Centre for Medicine Use and Safety (CMUS) at the Monash Institute of Pharmaceutical Sciences has participated in and led discussions at a new international collaboration of data scientists called the Neurodegenerative Diseases Global Epidemiology Network (NeuroGEN).
NeuroGEN harnesses the power of big data to generate new high quality evidence related to the benefits and risks of medication use in people with dementia and other neurodegenerative diseases.
Meeting at University College London last week, the NeuroGEN collaboration now includes representatives from the disciplines of pharmacy, neurology, geriatrics, cardiology, health economics, social sciences, biostatistics and epidemiology. NeuroGEN participants come from Australia, China, England, Finland, Germany, Hong Kong, Korea, Scotland, Taiwan and the United States.
CMUS Research Fellow Dr Jenni Ilomaki was appointed inaugural Convenor of NeuroGEN. Dr Ilomaki said “bringing together data and researchers from across the world creates new possibilities to share expertise and make a global impact”.
NeuroGEN evolved out of the International Pharmaceutical Informatics Initiative (IPI2): Big Data Research Platform that was originally funded through a PharmAlliance scheme. The Platform has received subsequent funding through the Victorian Medical Research Acceleration Fund and Dementia Australia Research Foundation – Yulgilbar Innovation Grant.
PharmAlliance is a partnership between three of the world's most highly-regarded pharmacy schools – Monash University, University College London and the University of North Carolina at Chapel Hill.